The data of the Non-rheumatic Valvular Heart Disease and their Subtypes globally from the Global Burden of Disease 2023

BackgroundNon-rheumatic valvular heart disease (NRVHD) is a valvular dysfunction disease, including non-rheumatic degenerative mitral valve disease (DMVD), non-rheumatic calcific aortic valve disease (NRCAVD) and other NRVHD. The mortality of NRVHD and their subtypes continues to rise with the aging of the population. Based on Global Burden of Disease (GBD) 2023 data, we systematically analyzed the burden of NRVHD and their subtypes globally and in Asia from 1990 to 2023, and projected trends by 2050.MethodsThe mortality and disability-adjusted life years (DALYs) rates were extracted to analyze the disease burden of NRVHD and their subtypes across regions, countries, age groups and genders. Joinpoint regression analysis was used to assess temporal and regional trends. Age-Period-Cohort (APC) model was used to analyze trends in disease burden changes by age and year. The BAPC models were used to forecast disease trends up to 2050.ResultsIn 2023, the deaths cases for NRVHD, NRCAVD, DMVD and other NRVD globally were 191358 (95% UI: 157502, 215074), 149460 (95% UI: 120529, 166659), 39768 (95% UI: 32430, 51510) and 2129 (95% UI: 1314, 3327). In Asia, NRVHD and DMVD showed downward trend, but NRCAVD showed upward trend. In Georgia, average annual percent change (AAPC) of age-standardized DALYs rate (ASDR) reached 4.95 (95% CI: 3.29, 6.64) for NRVHD. Compared with 1990, the number of DALYs and deaths in all gender increased in elderly populations but decreased in young populations in 2023. The burden for females was higher than those for males. The epidemiological indicators displayed positive correlation in high-middle SDI, especially influenced by High-income Asia Pacific for NRVHD, NRCAVD and DMVD. In the age effect, the relative risks markedly increased after the age of 75 in global and Asia. By 2050, ASDR and ASMR will continue to rise for NRVHD and their subtypes globally and in Asia, with ASMR of NRVHD in 2050 at 2.64 (95% UI: -0.51, 5.80) globally and 1.54 (95% UI: -1.85, 4.93) in Asia.ConclusionFrom 1990 to 2023, the burden of NRVHD and their subtypes globally showed upward trend, and the disease burden still concentrated in elder populations. Through in-depth research on these trends, key information is provided for targeted intervention.